Cardiff Oncology Inc
For the period ended Dec 31, 2024. Filed Feb 27, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 27, 2025
CRDF$0.80+5.3%Stored close · as of Nov 6, 2026
Contents
Statements of Operations
(in thousands, except per share amounts)
| Year Ended December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Royalty revenues | $683 | $488 |
| Costs and expenses: | ||
| Research and development | 36,852 | 32,857 |
| Selling, general and administrative | 12,482 | 13,043 |
| Total operating expenses | 49,334 | 45,900 |
| Loss from operations | (48,651) | (45,412) |
| Other income (expense), net: | ||
| Interest income, net | 3,259 | 4,069 |
| Other expense, net | (39) | (98) |
| Total other income, net | 3,220 | 3,971 |
| Net loss | (45,431) | (41,441) |
| Preferred stock dividend payable on Series A Convertible Preferred Stock | (24) | (24) |
| Net loss attributable to common stockholders | $(45,455) | $(41,465) |
| Net loss per common share — basic and diluted | $(0.95) | $(0.93) |
| Weighted-average shares outstanding — basic and diluted | 47,650 | 44,677 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.